Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin’s lymphoma

Lin Gui, Xiaohong Han, Xiaohui He, Yuanyuan Song, Jiarui Yao, Jianliang Yang, Peng Liu, Yan Qin, Shuxiang Zhang, Weijing Zhang, Wenlin Gai, Liangzhi Xie, Yuankai ShiChinese 2016 · DOI

Abstract

SCT400 is well-tolerated and has encouraging preliminary efficacy in Chinese patients with CD20(+) B-cell NHL.
BibTeX
@inproceedings{gui2016phase,
  author = {Lin Gui and Xiaohong Han and Xiaohui He and Yuanyuan Song and Jiarui Yao and Jianliang Yang and Peng Liu and Yan Qin and Shuxiang Zhang and Weijing Zhang and Wenlin Gai and Liangzhi Xie and Yuankai Shi},
  title = {{Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin’s lymphoma}},
  booktitle = {Chinese},
  year = {2016},
  doi = {10.21147/j.issn.1000-9604.2016.02.07},
}

Loading related content...

Figure